Evidence map›Paper›PMID 25453426›Full record

ReviewClinics in chest medicine2014

Endogenous and exogenous cell-based pathways for recovery from acute respiratory distress syndrome.

Jeffrey E Gotts, Michael A Matthay

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in chest medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05191381 (Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05191381 recruitingnot on this mapstarted 2021, after this paper: background citation

Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19

Typeobservational_patient_registrySponsorUniversity of UlmRan2021 to 2026Enrolled40ConditionsCOVID-19, Critical Illness, Hypercytokinemia, Lung FibrosisArmsApplication of exosomes in a whole blood assay
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jeffrey E GottsDepartments of Medicine and Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0624, USA.
Michael A MatthayDepartments of Medicine and Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0624, USA. Electronic address: Michael.matthay@ucsf.edu.

Funding

MECHANISMS OF ALVEOLAR EPITHELIAL FLUID CLEARANCER01HL051854 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHAY, MICHAEL A. · 1994 to 2012
$4.4M
Resolution of Clinical Lung InjuryR37HL051856 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHAY, MICHAEL A. · 2006 to 2015
$3.9M
Mechanisms of Mesenchymal Stem Cell Therapy in Viral-Induced Acute Lung InjuryF32HL117549 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOTTS, JEFFREY E · 2013 to 2013
$35k
NHLBI NIH HHS F32 HL117549NHLBI NIH HHS F32HL117549NHLBI NIH HHS R01 HL051854NHLBI NIH HHS R01HL51854NHLBI NIH HHS R37 HL051856NHLBI NIH HHS R37HL51856
6 · The paper itself

Abstract

Regenerative medicine has entered a rapid phase of discovery, and much has been learned in recent years about the lung's response to injury. This article first summarizes the cellular and molecular mechanisms that damage the alveolar-capillary barrier, producing acute respiratory distress syndrome (ARDS). The latest understanding of endogenous repair processes is discussed, highlighting the diversity of lung epithelial progenitor cell populations and their regulation in health and disease. Finally, the past, present, and future of exogenous cell-based therapies for ARDS is reviewed.

Indexed as

Cell- and Tissue-Based TherapyHumansRespiratory Distress SyndromeAcute respiratory distress syndromeLung progenitor cellsMesenchymal stem/stromal cells

Identifiers

PMID25453426
PMCPMC4254691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.